DR. JACK L ARBISER, MD
Dermatology at Clifton Rd, Atlanta, GA

8030299, Oct 4, 2011

May 21, 2009

12/470008

Jack Arbiser - Atlanta GA, US

A61K 31/43, A61K 33/26, A01N 59/16

514192, 424646

Melanoma is a solid tumor that is notoriously resistant to chemotherapy, and its incidence is rapidly increasing. Recently, several signaling pathways have been demonstrated to contribute to melanoma tumorigenesis, including constitutive activation of MAP kinase, Akt and stat-3. The activation of multiple pathways may account in part for the difficulty in treatment of melanoma. In a recent screen of compounds, we found that an organopalladium complex showed significant antiproliferative activity against melanoma cells. This complex, tris(dibenzylideneacetone)dipalladium (Tris DBA), has activity against B16 murine and A375 human melanoma in vivo. Tris DBA inhibits several signaling pathways including activation of MAP kinase, Akt, stat-3 and S6 kinase activation. Tris(dibenzylideneacetone)dipalladium is thus a novel compound that is a member of a class of noble metal complexes with potential antitumor activity. Further preclinical evaluation of TrisDBA and related complexes is warranted.

2009001, Jan 15, 2009

Oct 25, 2007

11/924567

Jack L. Arbiser - Atlanta GA, US

A61K 31/12, A61P 1/00

514679

Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.

2013033, Dec 19, 2013

Aug 20, 2013

13/970639

Jack L. Arbiser - Atlanta GA, US

U.S. GOVERNMANET AS REPRESENTED BY UNITED STATES DEPARTMENT OF VETERANS AFFAIRS - Washington DC
EMORY UNIVERSITY - Atlanta GA

C07D 209/14

514414, 548457

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.

2010018, Jul 29, 2010

Dec 21, 2009

12/643418

Jack L. Arbiser - Atlanta GA, US

EMORY UNIVERSITY - Atlanta GA

A61K 9/00, C07D 243/12, C07D 337/12, C07D 313/12, C07D 285/36, C07D 417/06, A61K 31/551, A61K 31/38, A61K 31/335, A61K 31/553, A61K 31/5415, A61P 35/00

424423, 540495, 549 12, 549354, 540489, 544 44, 514220, 514431, 514450, 51421108, 5142258

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.

2004010, Jun 3, 2004

Sep 23, 2003

10/472512

Jack Arbiser - Atlanta GA, US
Xianhe Bai - Tucker GA, US

A61K035/78

424/770000

Pharmaceutical compositions and methods of treating conditions such as angiogenic-, neoplastic-, and cancer-related conditions and skin conditions are disclosed. The methods include administering to a host in need of treatment an effective amount of at least one honokiol-type compound and/or at least one magnolol-type compound. In addition, the pharmaceutical compositions include at least one honokiol-type compound and/or at least one magnolol-type compound in combination with a pharmaceutically acceptable carrier. The honokiol-type compound and/or magnolol-type compound are present in a dosage level effective to treat conditions listed above.

2009017, Jul 9, 2009

Dec 29, 2008

12/345652

Jack L. Arbiser - Atlanta GA, US

Emory University - Atlanta GA

A61K 31/662, C07D 223/28, A61K 31/55, C07F 9/40, A61K 31/47, C07D 215/26, C07D 279/24, A61K 31/54, A61K 31/553, C07D 413/04, A61P 35/00

514114, 540588, 514217, 558190, 514311, 546177, 544 41, 5142262, 51421113, 540551

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.

8168657, May 1, 2012

Jan 24, 2003

10/502080

J. Phillip Bowen - Hull GA, US
Jack L. Arbiser - Atlanta GA, US
David Whitmire - Atlanta GA, US
M. Scott Furness - Bethesda MD, US

A61K 31/445

514315

The present invention relates to solenopsin A and its analogs for use as angiogenesis inhibitors. The present compounds unexpectedly exhibit good activity as angiogenesis inhibitors, which find use as antitumor/anticancer agents as well as to treat a number of conditions or disease states in which angiogenesis is a factor.

2004009, May 20, 2004

Sep 25, 2003

10/473171

Jack Arbiser - Atlanta GA, US

A61K031/203

514/559000

Pharmaceutical compositions and methods of treating ulcerating diseases, burns, and related conditions are disclosed. The methods include administering to a host in need of treatment an effective amount of at least one retinoid receptor compound. In addition, the pharmaceutical compositions include at least one retinoid receptor compound in combination with a pharmaceutically acceptable carrier. The retinoid receptor compound can be present in a dosage level effective to treat conditions listed above.